IL6 and neoplasm: Of note, the diffusion of checkpoint inhibitors based immunotherapy for a growing number of cancers [40], the use of combination checkpoint inhibitors like ipilimumab plus nivolumab (with a significant risk of immune toxicity) [41–43], coupled with the implementation of ipilimumab for the adjuvant therapy of melanoma [44, 45], should invite to extend the use of sex and IL6 for AEs risk estimation in patients affected with tumours other than melanoma and treatment setting other than metastatic.